Skip to main content
. Author manuscript; available in PMC: 2020 Sep 2.
Published in final edited form as: J Neurooncol. 2020 Apr 27;148(2):231–244. doi: 10.1007/s11060-020-03517-5

Fig. 2. LB-100 and PD-1 blockade synergistically elicit tumor rejection in a CD8+ and CD4+ T cell dependent manner.

Fig. 2

(a) C57BL/6 mice were inoculated with 1.3×106 GL261 cells and treated as above with combination therapy beginning on post-operative day 8. Mice were given CD8+ and/or CD4+ T cell depleting antibodies on post-operative day 6 and 8, then weekly until endpoint. (b) Cumulative survival of mice over time. All experiments were duplicated with 8 mice per group. The combined data was presented